OPKO Health (OPK) to Present Positive Data from Rayaldee Phase 3 in SHPT
Tweet Send to a Friend
OPKO Health (NYSE: OPK) announces that additional Phase 3 data on Rayaldee™ as a treatment for secondary hyperparathyroidism (SHPT) will ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
